Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna has agreed to a significant patent settlement, paying up to $2.25 billion to Arbutus Biopharma and Genevant Sciences to resolve litigation over its Covid-19 vaccine technology. The agreement includes an upfront payment of $950 million, with an additional $1.3 billion contingent on the outcome of a related appeal. This resolution, which averts a trial scheduled for next week, is a material positive development for Moderna, removing a substantial legal and financial overhang. While the payment is large, analysts view it as avoiding a potentially worse-case scenario, providing clarity on a major liability. This follows recent news of Moderna's intention to appeal a prior ruling in a patent dispute, highlighting the company's ongoing legal challenges which this settlement now partially resolves. Investors will now monitor the outcome of the appeal that could trigger the additional payment.
At the time of this announcement, MRNA was trading at $53.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3B. The 52-week trading range was $22.28 to $56.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.